A Prospective Real-world Study to Assess Safety, Tolerability, and Effectiveness of Imeglimin among People with Type 2 Diabetes Mellitus Who are Intolerant to Metformin (PRISM Study).
Agrawal, Prabhat Kumar, Ketan K Mehta, Abhisekh Raha, Rajesh Agarwal, Amit Varshney, Amitabh Biswas, Kiran Sharadchandra Shah, et al. 2026. “A Prospective Real-World Study to Assess Safety, Tolerability, and Effectiveness of Imeglimin Among People With Type 2 Diabetes Mellitus Who Are Intolerant to Metformin (PRISM Study).”. The Journal of the Association of Physicians of India 74 (1E): e1-e7.